Espinoza-Gutarra Manuel R, Collins Jennifer, Kennedy Vanessa, Randall Jill, Su Christopher T, Banerjee Rahul, Wuliji Natalie, Odstricil-Bobillo Silvina, Amonoo Hermioni L, Wood William A, Hamilton Betty, Sung Anthony, Lee Catherine J
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama.
University of Chicago, Chicago, Illinois.
Transplant Cell Ther. 2025 Jul 23. doi: 10.1016/j.jtct.2025.07.017.
Social determinants of health (SDOH) are an increasingly recognized prognostic factor in patients undergoing hematopoietic cell transplantation (HCT) and chimeric antigen receptor-T cell (CAR-T) therapy. However, awareness among providers of their importance and appropriate evaluation of SDOH factors in transplant candidates is insufficient in standard clinical practice and in research. As part of a coordinated effort by 3 American Society for Transplantation and Cellular Therapy (ASTCT) Special Interest Groups, we have developed a general overview of SDOH in transplantation and cellular therapy (TCT) along with suggested best practices. We strongly encourage the assessment of SDOH pre-TCT by a trained member of the team as well as the development of a communication plan tailored to an individual patient's background. Other recommendations include the development and validation of longitudinal instruments for SDOH evaluation in patients undergoing TCT, with emphasis on those that use primary sources of information, the inclusion of SDOH in outcome and mortality benchmarks established by regulatory bodies, and the development of intervention strategies in the context of clinical trials.
健康的社会决定因素(SDOH)在接受造血细胞移植(HCT)和嵌合抗原受体T细胞(CAR-T)治疗的患者中日益被视为一种预后因素。然而,在标准临床实践和研究中,医疗服务提供者对其重要性的认识以及对移植候选者的SDOH因素进行适当评估的情况并不充分。作为美国移植与细胞治疗学会(ASTCT)3个特别兴趣小组协同努力的一部分,我们编写了一份关于移植与细胞治疗(TCT)中SDOH的概述以及建议的最佳实践方法。我们强烈鼓励由团队中经过培训的成员在TCT前对SDOH进行评估,并制定针对个体患者背景的沟通计划。其他建议包括开发和验证用于评估接受TCT患者的SDOH的纵向工具,重点是那些使用主要信息来源的工具,将SDOH纳入监管机构制定的结果和死亡率基准中,以及在临床试验背景下制定干预策略。